Filed by Sanofi-Aventis
                                  Pursuant to Rule 165 and Rule 425(a) under the
                                           United States Securities Act of 1933,
                                                                      as amended

                                                        Subject Company: Aventis
                                                   Commission File No. 001-10378
                                                         Date: November 26, 2004


     On November 25, 2004, Sanofi-Aventis issued the following press release.

     In  connection   with  the  proposed   merger  of  Aventis  with  and  into
Sanofi-Aventis,  Sanofi-Aventis  has  filed a  post-effective  amendment  to its
registration  statement  on Form F-4 (File no.  333-112314),  which  includes  a
definitive  prospectus  relating  to the  Sanofi-Aventis  shares to be issued to
Aventis  shareholders  resident  in the U.S.  in  connection  with the  proposed
merger,  and may file additional  documents with the SEC. Investors are urged to
read the registration  statement,  including the definitive prospectus,  and any
other  relevant  documents  filed with the SEC,  including  all  amendments  and
supplements, because they will contain important information. Free copies of the
registration  statement, as well as other relevant documents filed with the SEC,
may be obtained at the SEC's web site at www.sec.gov. The prospectus relating to
the  Sanofi-Aventis  shares to be issued to Aventis  shareholders  in connection
with the proposed merger has been mailed to Aventis security holders resident in
the U.S. and additional copies may be obtained for free from MacKenzie Partners,
Inc., the U.S. information agent for the merger, at the following address:  105,
Madison  Avenue,  New York, New York 10016;  telephone:  1-(212)  929-5500 (call
collect)     or     1-(800)     322-2885      (toll-free      call);      e-mail
proxy@mackenziepartners.com. .



                                     * * * *




                             [SANOFI-AVENTIS LOGO]


                                                        Paris, November 25, 2004



                  PROPOSED RELOCATION OF AVENTIS' HEADQUARTERS
                            FROM STRASBOURG TO PARIS


Since  April 26,  2004,  when  Sanofi-Synthelabo  and  Aventis  agreed to create
sanofi-aventis,  it  has  been  confirmed  that  the  headquarters  of  the  new
sanofi-aventis Group is to be located in Paris.

Sanofi-aventis  announced  today that the Aventis site  located in  Schiltigheim
will cease its activity  during the course of next year.  The business  activity
will be transfered to Paris.

The French Works Council - << Comite  d'Entreprise >> - of the Schiltigheim site
was  informed  about this  proposed  relocation  during the meeting  held today,
November 25, 2004.

Aventis employs a staff of 220 in Schiltigheim, as well as 60 service providers.

In accordance with the Group's  employment policy, a series of measures intended
to facilitate staff mobility will be implemented with the aim of redeploying all
employees.

Management  has also expressed its intention of continuing to work together with
all  the   scientific,   economic  and  social  bodies  in  the  Alsace  region,
particularly in the area of Research, through its Research center in Strasbourg.

In addition, in order to minimize the impact that this transfer of activities to
the Paris area will have on local employment, the SOPRAN company, a wholly-owned
subsidiary of the Group, has been instructed to look for new business activities
favoring employment in the Alsace region.


ABOUT SANOFI-AVENTIS
The  sanofi-aventis  Group is the world's 3rd  largest  pharmaceutical  company,
ranking  number  1  in  Europe.   Backed  by  a  world-class  R&D  organization,
sanofi-aventis is developing leading positions in seven major therapeutic areas:
cardiovascular disease, thrombosis,  oncology, diabetes, central nervous system,
internal  medicine,  vaccines.  The  sanofi-aventis  Group  is  listed  in Paris
(EURONEXT : SAN) and in New York (NYSE : SNY).


INVESTOR RELATIONS DEPARTMENT

Europe                                  US
Tel : + 33 1 53 77 45 45                Tel. : + 1 212 551 40 18

E-mail : IR@sanofi-aventis.com



                             [SANOFI-AVENTIS LOGO]


This press release contains forward-looking statements as defined in the Private
Securities  Litigation  Reform  Act  of  1995.  Forward-looking  statements  are
statements that are not historical facts.  These statements  include  statements
regarding plans,  objectives and expectations with respect to future operations,
products  and   services,   and   statements   regarding   future   performance.
Forward-looking  statements  are generally  identified  by the words  "expects,"
"plans," "anticipates,"  "believes," "intends," "estimates",  "aims" and similar
expressions.  Although sanofi-aventis' management believes that the expectations
reflected in such  forward-looking  statements  are  reasonable,  investors  are
cautioned that forward-looking information and statements are subject to various
risks and  uncertainties,  many of which are  difficult to predict and generally
beyond the  control of  sanofi-aventis,  that could  cause  actual  results  and
developments  to differ  materially  from  those  expressed  in, or  implied  or
projected by, the  forward-looking  information  and  statements.  The following
factors,  in addition to the risks and uncertainties  discussed or identified in
the public filings with the SEC and the AMF made by sanofi-aventis  and Aventis,
including those listed under "Forward-Looking  Statements" and "Risk Factors" in
sanofi-aventis's annual report on Form 20-F for the year ended December 31, 2003
and  those  listed  under  "Cautionary   Statement   Regarding   Forward-Looking
Statements"  and "Risk Factors" in Aventis's  annual report on Form 20-F for the
year ended December 31, 2003,  could cause actual  results to differ  materially
from  those  described  in  forward-looking   statements:  the  ability  of  the
management of  sanofi-aventis to implement its integration plans in a timely and
efficient manner. Other than as required by applicable law,  sanofi-aventis does
not undertake any obligation to update or revise any forward-looking information
or statements.


IMPORTANT INFORMATION.
In connection with the proposed merger of Aventis with and into  sanofi-aventis,
sanofi-aventis  has  filed  a  post-effective   amendment  to  its  registration
statement  on Form F-4  (File  no.  333-112314),  which  includes  a  definitive
prospectus  relating  to the  sanofi-aventis  shares  to be  issued  to  Aventis
shareholders  resident in the U.S. in connection with the proposed  merger,  and
may file  additional  documents  with the SEC.  Investors  are urged to read the
registration  statement,  including  the  definitive  prospectus,  and any other
relevant documents filed with the SEC, including all amendments and supplements,
because they will contain important information. Free copies of the registration
statement,  as well as other  relevant  documents  filed  with  the SEC,  may be
obtained at the SEC's web site at  www.sec.gov.  The prospectus  relating to the
sanofi-aventis  shares to be issued to Aventis  shareholders  in connection with
the proposed merger has been mailed to Aventis  security holders resident in the
U.S. and  additional  copies may be obtained for free from  MacKenzie  Partners,
Inc., the U.S. information agent for the merger, at the following address:  105,
Madison  Avenue,  New York, New York 10016;  telephone:  1-(212)  929-5500 (call
collect)     or     1-(800)     322-2885      (toll-free      call);      e-mail
proxy@mackenziepartners.com.






INVESTOR RELATIONS DEPARTMENT

Europe                                  US
Tel : + 33 1 53 77 45 45                Tel. : + 1 212 551 40 18

E-mail : IR@sanofi-aventis.com